fitusiran
Selected indexed studies
- Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. (Blood, 2024) [PMID:38452197]
- Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. (Lancet, 2023) [PMID:37003287]
- Fitusiran: First Approval. (Drugs, 2025) [PMID:40579682]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. (2024) pubmed
- Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. (2023) pubmed
- Fitusiran: First Approval. (2025) pubmed
- Fitusiran. (2006) pubmed
- Fitusiran. (2012) pubmed
- Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. (2025) pubmed
- Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. (2023) pubmed
- Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels. (2025) pubmed
- Qfitlia (fitusiran). (2025) pubmed
- Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. (2025) pubmed